Clearmind Medicine Inc. (CMND)
| Market Cap | 2.70M +418.6% |
| Revenue (ttm) | n/a |
| Net Income | -7.50M |
| EPS | -118.41 |
| Shares Out | 420.88K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,566 |
| Open | 6.24 |
| Previous Close | 6.29 |
| Day's Range | 6.24 - 6.79 |
| 52-Week Range | 1.76 - 384.00 |
| Beta | 0.46 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 10, 2026 |
About CMND
Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. It develops MEAI compound for the treatment of alcohol use disorder, obesity, and metabolic disorders, as well as an alcohol substitute consumer product; a... [Read more]
Financial Performance
Financial StatementsNews
Clearmind Medicine’s Charging Robotics launches robotaxi charging platform
Clearmind Medicine (CMND) announced that Charging Robotics, its 51%-owned subsidiary, has launched the next generation of its autonomous vehicle charging platform, designed for robotaxis, autonomous f...
Clearmind Medicine publishes patent application in Japan for treating dyskinesia
Clearmind Medicine (CMND) announced the publication of a patent application in Japan covering novel compositions and methods for treating dyskinesia, a neurological movement disorder characterized by ...
Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder
Published patent application covers 3-MMC-based treatment of dyskinesia, including in combination with Palmitoylethanolamide (PEA) Vancouver, Canada, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Clearmind Medici...
Clearmind Medicine submits psychedelic therapy recommendations to FDA
Clearmind Medicine (CMND) announced it submitted recommendations to the FDA under Docket FDA-2026-N-7542 on future therapeutic use of psychedelic drugs, urging guidance for self-administration and at-...
Clearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDA
Company Calls for Consideration of New Regulatory Pathways and Cost Saving of Non-Hallucinogenic Neuroplastogens for Alcohol Use Disorder
Clearmind Medicine Inc trading halted, news pending
19:50 EDT Clearmind Medicine (CMND) Inc trading halted, news pending
SciSparc expands U.S. IP portfolio in collaboration with Clearmind Medicine
SciSparc (SPRC) announced that NeuroThera Labs highlighted the expansion of the U.S. intellectual property, IP, portfolio through its ongoing collaboration with Clearmind Medicine (CMND). As part of t...
NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations
The U.S. patent applications cover proprietary combinations of NeuroThera's PEA technology with LSD, ketamine and ibogaine for potential therapeutic applications, including mental health disorders, su...
Clearmind Medicine announces publication in U.S. of 3 patent applications
Clearmind Medicine (CMND) announced the publication in the United States of three patent applications covering novel proprietary combinations of lysergic acid diethylamide, ketamine and ibogaine with ...
Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations
The covered applications address potential therapeutic uses across a range of indications, including mental health disorders, such as depression and PTSD as well as substance use disorders
Stickit Technologies Announces Corporate Update: Leadership Appointments, Capital Restructuring & Loan Acquisition, And Update Of Intellectual Property Portfolio
VANCOUVER, BC September 17, 2026 - TheNewswire — StickIt Technologies Inc. (CSE: STKT) (the "Company" or "StickIt"), a developer and patent holder of proprietary cannabinoid and plant extract delivery...
Clearmind Medicine briefs FDA following psychedelic hearing in Washington D.C.
Clearmind Medicine (CMND) announced that, following an invitation from the FDA, it testified at the FDA’s psychedelic hearing in the nation’s capital on September 14. Clearmind’s chief of global impac...
Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C.
Mary-Elizabeth Gifford, Chief of Global Impact at Clearmind Medicine, spoke on patient access and shared insights from Clearmind's clinical trial at Yale and Johns Hopkins
Clearmind Medicine enrolls first patients with AUD in CMND-100 trial
Clearmind Medicine (CMND) announced the enrollment of the first patients with Alcohol Use Disorder in its ongoing clinical trial evaluating CMND-100, the company’s proprietary psychedelic-based treatm...
Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial
Vancouver, Canada, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derive...
Clearmind Medicine Earnings release: Q3 2026
Clearmind Medicine released its Q3 2026 earnings on September 10, 2026, summarizing the period's financial results.
Clearmind Medicine announces Yale IRB approval of Parts B, C of CMND-100 trial
Clearmind Medicine (CMND) announced that the Yale University’s IRB has approved the initiation of patient recruitment for Parts B and C of its Phase I/II clinical trial evaluating CMND-100. This…
Clearmind Medicine Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial, Following Positive Safety Results
Vancouver, Canada, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the “Company” or “Clearmind”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psy...
Clearmind Medicine to acquire 51% stake in Charging Robotics
Clearmind Medicine (CMND) announced that it has entered into a definitive agreement to acquire a 51% stake in Charging Robotics, an intelligent EV wireless charging solutions for automated parking sys...
Clearmind Medicine Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis
Charging Robotics is one of the few worldwide developing innovative wireless charging systems designed specifically for automated parking facilities and autonomous mobile platforms- environments wher...
Clearmind Medicine initiates next stage of CMND-100 trial for treatment of AUD
Clearmind Medicine (CMND) announced the initiation of Phase lla, the next stage of its double-blind, placebo-controlled Phase I/IIa clinical trial evaluating CMND-100 for the treatment of AUD, with si...
Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled
Vancouver, Canada, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derive...
Psychedelic: SciSparc, Clearmind publish patent application for PTSD treatment
“Psychedelic” is The Fly’s recurring series focused on psychedelic stock news. SCISPARC/CLEARMIND: SciSparc (SPRC) announced earlier this week that its subsidiary, NeuroThera Labs, and Clearmind Medic...
SciSparc, Clearmind publish U.S. patent application for MDMA-PEA combination
SciSparc (SPRC) announced that its subsidiary, NeuroThera Labs, and Clearmind Medicine (CMND) have published a U.S. patent application covering a novel combination of MDMA and N-acylethanolamines, suc...
NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation
U.S. publication of a patent application covering the MDMA-N-acylethanolamines combination expands intellectual property generated through the collaboration, and provides guidance addressing clinical ...